InvestorsHub Logo
Followers 35
Posts 1771
Boards Moderated 0
Alias Born 09/25/2012

Re: Shadowfaxin post# 119114

Saturday, 10/31/2015 10:26:29 AM

Saturday, October 31, 2015 10:26:29 AM

Post# of 130513
I can't argue you with you on that statement. For instance what's up with posting that ESS news for 13 year followup. Old news rehashed to boost share price. Anyways AMBS shouldn't be focusing on a dermatology indication ESS. Should be focusing on its neorology pipeline.